PharmaTelevision - PolyTherics Ltd: PEGylation and the Polytherics Business Model

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: PolyTherics Ltd: PEGylation and the Polytherics Business Model

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Sally Waterman, Chief Operating Officer at PolyTherics Ltd. Filmed at BioTrinity 2010 in Newbury, UK, they discuss:

• Origins and PEGylation technologies of PolyTherics

• Whats unique about PEGylation methodology?

• The importance of reduction of cost of goods for the types of proteins of therapeutic use

• PEGylation vs non PEGylation technologies

• Business model and collaborations -

• Future goals

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Origins and PEGylation technologies of PolyTherics

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioTrinity in Newbury, Berkshire in the United Kingdom. On this show I have Sally Waterman, who is the Chief Operating Officer for a company called PolyTherics based in London, welcome. Tell me a little bit more about PolyTherics , what is the company and what is its unique proposition?

Sally Waterman:

PolyTherics was founded with technology from the London School of Pharmacy and grant funding from the Wellcome Trust and it was formed in 2002 it's received its first investors money in 2007, 2.3 million provided by Imperial Innovations, Longbow Capital and The Capital Fund and that same syndicate of investors invested another 3 million earlier this year and that money is being used to develop three very particular site-specific PEGylation technologies and between those technologies the company can PEGylate almost any protein or peptide of any type.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Sally Waterman

COO

Dr. Sally Waterman Chief Operating Officer; her previous responsibilities include Director of Research & Development at Protherics (now part of BTG), global drug development and a polymer research group in Salt Lake City and with KS Biomedix (acquired by Xenova), and also on non-clinical development at Vernalis.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

PolyTherics Ltd

PolyTherics is a company dedicated to using biomedical polymers to optimize pharmaceuticals, in particular biopharmaceuticals, for the treatment and cure of the world's most important diseases. PolyTherics 's most advanced programmes are designed to exploit TheraPEG technology, an innovative, patent protected approach to the PEGylation of therapeutic proteins and antibody fragments. Through the targeted attachment of PEG via naturally occurring disulfide bonds within proteins, biochemical and biophysical properties can be altered without compromising biological activity. Beyond targeted PEGylation, PolyTherics has developed proprietary polymer-based technologies for application to both small molecules and large proteins, to create a broad portfolio of improved medicines.